Table 3:

Evidence profile and pooled effect estimates to inform PICO 1 (H Pylori)

Certainty Assessment							No of Patients		Effect
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	Test/Treat for H Pylori	No Test/Treat	Relative (95% CI)	Absolute (95% CI)	Certainty	Importance
Relative risk of death (All-cause mortality) among patients with H. pylori infection after H. pylori treatment versus placebo (all patients, with or without GIM)
3	RCTs	Not serious	Not serious	Serious2	Serious3	None	180/2202 (8.2%)	169/2199 (7.7%)	RR=1.07 (0.88–1.31)	5 more per 1000 (from 9 fewer to 24 more)	⊕⊕○○ Low	Critical
Relative risk of gastric cancer-related mortality among patients with H. pylori infection after H pylori treatment versus placebo (all patients, with or without GIM)
2	RCTs	Not serious	Not serious	Serious2	Serious3	None	20/1947 (1.0%)	30/1941 (1.5%)	RR=0.67 (0.38–1.17)	5 fewer per 1000 (from 3 more to 10 fewer)	++ Low	Critical
Relative risk of incident gastric cancer among patients with H. pylori infection after H pylori treatment versus placebo (all patients, with or without GIM)
6	RCTs and cohort1	Not serious	Not serious	Serious2	Not serious	None	52/3810 (1.4%)	78/4722 (1.7%)	RR=0.68 (0.48–0.96)	6 fewer per 1000 (1 fewer to 9 fewer)	+++ Moderate	Critical
Relative risk of incident gastric cancer among patients with H. pylori infection and confirmed GIM after H pylori treatment versus placebo
3	RCTs	Not serious	Not serious	Not serious	Very serious3	None	12/800 (1.5%)	16/813 (2.0%)	RR=0.76 (0.36–1.61)	3 fewer per 1000 (from 14 fewer to 20 more)	++ Low	Critical

CI: Confidence interval; RR: Risk Ratio

¹⁾4 RCTs and 2 observational cohort. Results are driven by RCTs findings

²⁾Data considered in all patients, not just patients with GIM

³⁾Few events, confidence intervals are wide encompassing both considerable benefit and harm.